T2 Biosystems Priced, Nasdaq: TTOO
Developing diagnostic tests to screen for sepsis and impaired hemostasis.
Industry: Health Care
First Day Return: +30.2%
Industry: Health Care
TTOO
Developing diagnostic tests to screen for sepsis and impaired hemostasis.
| IPO Data | |
|---|---|
| IPO File Date | 07/02/2014 |
| Offer Price | $11.00 |
| Price Range $15.00 - $17.00 | |
| Offer Shares (mm) | 5.2 |
| Deal Size ($mm) | $57 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 08/06/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $57 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Lexington, MA, United States |
| Founded | 2006 |
| Employees at IPO | 68 |
| Website www.t2biosystems.com | |
IPO News for T2 Biosystems
T2 Biosystems (TTOO) Performance
